FUJIFILM Corporation is investing $21 million via its US subsidiary to open a new cGMP-compliant production facility for the production of human iPS cell therapy applications.
FUJIFILM Cellular Dynamics Inc (FCDI) said the facility will support its internal cell therapeutics pipeline.
It will also serve as a contract development ad manufacturing organisation for its iPS cell products.
“To meet the growing demand for FCDI’s iPS cell platform, the state-of-the-art production facility will have a flexible cell culturing design to serve production requirements of both industrial quantities of cells, and small, diverse batches,” said Seimi Satake, Chairman and CEO of FCDI.
“By combining Fujifilm’s experience gleaned from the intricate process of manufacturing photographic film along with FCDI’s knowledge of cell reprogramming, genetic engineering and cell differentiation, the facility is poised to address the complex manufacturing processes of cell therapies.”
With the facility operational by March 2020, FCDI said it intends to accelerate the development of its internal pipeline to address unmet medical needs in areas such as age-related macular degeneration, retinitis pigmentosa, Parkinson’s disease, heart diseases, and cancer.